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Background: Chronic hepatitis B infection affects 240 million people, with the highest prevalence in Africa and
Asia, and results in 700 000 deaths annually. Access to diagnostics, particularly for hepatitis B virus viral load
quantiﬁcation (HBV DNA), is a major barrier to treatment. We aimed to test World Health Organization
guidelines for hepatitis B management in resource-limited settings.
Methods: We compared treatment allocation with and without the use of HBV DNA in a cohort in Uganda.
Hepatitis B surface antigen test–positive, human immunodeﬁciency virus–negative, treatment-naïve adults
were recruited prospectively. Following liver ultrasound and routine haematological and biochemical tests,
preliminary allocations into treatment and observation groups were made. HBV DNA was performed for each
participant and ﬁnal treatment decisions were made and compared with preliminary allocations.
Results: Full assessment was completed for 100 participants; treatment was indicated in 20. Assessment
without HBV DNA identiﬁed patients for treatment with a positive predictive value of 88.2% and a negative
predictive value of 94% compared with assessment using HBV DNA.
Conclusions: Where HBV DNA is unavailable, patients with hepatitis B can be assessed by liver ultrasound and
routine laboratory tests. These ﬁndings will enable physicians in resource-limited settings to initiate treatment
more readily and inform policy with regards to viral hepatitis elimination.
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Introduction
Chronic hepatitis B (CHB) affects 240 million people worldwide1
and kills around 700 000 people annually through the complica-
tions of hepatocellular carcinoma (HCC) and cirrhosis, predomin-
antly in low- and middle-income countries (LMICs).2,3 After a
long period of neglect,4 hepatitis B has become a focus of global
health policy. Following the World Health Assembly resolution
on viral hepatitis in 2014, the World Health Organization (WHO)
published guidelines for CHB in March 20155 and the Global
Health Sector Strategy on Viral Hepatitis in June 2016.6 These
documents describe a goal to eliminate viral hepatitis as a public
health threat by 2030, including a 65% reduction in mortality from
viral hepatitis, from a starting point in 2016 where <1% of indivi-
duals with viral hepatitis currently receive treatment. In the
absence of large-scale international funding, the onus is on mem-
ber countries to establish national guidelines and provide treat-
ment. Therapy with nucleoside reverse-transcriptase inhibitors such
as tenofovir controls viral replication,7 reverses ﬁbrosis8 and
reduces the risk of HCC.9 These drugs are safe and well tolerated
in CHB.10
One major barrier to drug treatment for hepatitis B is the
cost and availability of investigations that are currently con-
sidered key to patient assessment. Quantitative hepatitis B virus
(HBV) DNA viral load is performed by real-time polymerase chain
reaction (PCR) and non-invasive measures of hepatic ﬁbrosis
(e.g. transient elastography) are quantiﬁed by devices such as
FibroScan (transient elastography). Together with serum alanine
transaminase (ALT), these investigations are recommended to
inform treatment decisions in European,11 American12 and
Asian13 hepatitis B treatment guidelines but are too expensive
for many LMIC health care systems. One descriptive study of
the attitudes of hepatologists at a conference in West Africa
reported the cost and availability of investigations were major
reasons these were not performed.14 Another qualitative study
based on interviews of patients, their relatives and health care
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workers in Burkina Faso identiﬁed access and ability to pay as
major barriers to care.15 There are no robust alternatives for the
developing world and no guidelines for the management of
hepatitis B in Africa. The aspartate aminotransferase:platelet
ratio index (APRI) was developed for use in hepatitis C infection,
where it performs well but has poor sensitivity and speciﬁcity in
hepatitis B.16 The 2015 WHO guidelines5 include recommenda-
tions for management in settings where HBV DNA quantitation
is unavailable, including use of the APRI, but acknowledge
research gaps in the indications for initiating or deferring treat-
ment in sub-Saharan Africa. In the absence of funding for large-
scale screen-and-treat approaches,17 there is a need for simpli-
ﬁed clinical assessment of hepatitis B appropriate to LMICs in
order to achieve the treatment scale-up required to reduce
mortality.18
In Uganda, the prevalence of hepatitis B surface antigen
(HBsAg) carriage varies from 5% in the capital, Kampala, to 20%
in the rural north.19 A recent community prevalence survey in
Gulu Province demonstrated a prevalence of 17%.20 In response
to this high prevalence we wanted to establish the efﬁcacy of
substituting the use of both HBV DNA and ALT with the use of
ALT alone, based on WHO guidelines, as an affordable approach
to the assessment of CHB. Accordingly, we designed a pragmatic
study, based in the local health care infrastructure, as a real-
world test of this approach.
Methods
Study design and participants
A single arm prospective cohort study was used to compare
algorithms for treatment initiation. Patients were referred to the
study by clinical ofﬁcers and doctors at St Mary’s Hospital Lacor
from either outpatient or inpatient services if they had both a
positive HBsAg test and a negative human immunodeﬁciency
virus (HIV) test. Referrals were reviewed to ensure they met
entry criteria. Individuals whose HIV status was unknown were
offered testing. Patients were enrolled only if proven HIV nega-
tive. HIV-positive individuals were referred to the local HIV treat-
ment programme for treatment of HIV/HBV co-infection. The
study was explained and consent obtained in the local lan-
guage. A sample size of 103 was calculated to give 80% power
to detect a 15% difference between ‘ALT-based’ and ‘with HBV
DNA’ assessments by McNemar’s test.
Laboratory procedures
Clinical assessments were performed by the study clinical ofﬁcer
and reviewed by the study physician. In all patients, full blood
count (FBC), liver function tests (LFTs) and serum creatinine (SCr)
were measured by the St Mary’s Hospital Lacor clinical labora-
tory, using a Human Diagnostics 5L automated analyser
(Wiesbaden, Germany) and Humastar 600 clinical chemistry
platform (Wiesbaden, Germany). Gamma-glutamyl transferase
is not a part of the local liver function panel and was not mea-
sured. Liver ultrasound was performed and reported by sonogra-
phers at St Mary’s Hospital Lacor. Simulated allocation to
treatment by an ‘ALT-based’ algorithm (Figure 3) was made at
this stage, before viral load results were available. Hepatitis B
DNA viral load was measured in each patient by real-time PCR
using the COBAS AmpliPrep/COBAS TaqMan HBV test (Roche,
Basel, Switzerland).
Treatment
Treatment decisions were made independently by two authors
using the ‘with HBV DNA’ (Figure 2) assessment, discrepancies
were discussed and a ﬁnal management plan was agreed upon.
Individuals met treatment criteria if there was evidence of cirrhosis
(APRI>2 or ultrasound consistent with cirrhosis) or active hepatitis
attributable to HBV (ALT>50 IU/L and HBV DNA>20 000 IU/ml).
Patients allocated to treatment were offered tenofovir disoproxil
fumarate 300mg once daily, adjusted according to creatinine
clearance21 and followed up according to WHO recommenda-
tions.5 Patients allocated to the observation group were offered
follow-up by the hospital outpatient clinic. Tenofovir was donated
by Gilead Sciences (Foster City, CA, USA). Gilead Sciences had no
input into the study design or data analysis.
Statistical analysis
‘ALT-based’ assessments were compared with the ‘with HBV
DNA’ assessment as a reference standard. Statistical analysis
was performed in GraphPad Prism 7 (GraphPad Software, La
Jolla, CA, USA). Conﬁdence intervals for proportions were calcu-
lated using the Wilson–Brown method.
Ethics statement
The study protocol was approved by the Lacor Hospital
Institutional Research and Ethics Committee and the University
College London Research Ethics Committee and registered with
the Uganda National Council for Science and Technology. All
subjects provided informed consent. No children were recruited
into the study. Study information and consent forms were avail-
able in English and Luo. All participants were required to give
written consent for inclusion in the study.
Results
Patient ﬂow through the study is shown in Figure 1. A total of
103 patients with positive HBsAg and negative HIV tests were
referred to the study from both inpatient and outpatient ser-
vices. Two individuals declined to participate. A sample for HBV
DNA was not obtained from another participant, who was
excluded from the analysis. All other patients had full clinical
assessment and the following investigations: FBC, LFTs, SCr, liver
ultrasound scan and HBV DNA viral load PCR. Demographic and
clinical details are summarized in Table 1.
A total of 20 patients met the treatment criteria according to
the standard assessment with HBV DNA. Fourteen participants
were allocated to treatment due to cirrhosis, 12 with liver ultra-
sound ﬁndings consistent with chronic liver disease, and 2
patients with normal ultrasound scans had an APRI >2. A fur-
ther six individuals had active hepatitis as an indication for
treatment (Figure 2). In total, only eight individuals had an APRI
>2. Using treatment criteria of an APRI >2 or both ALT>50 IU/L
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and HBV DNA>20 000 IU/ml (i.e. without using liver ultrasound),
only 14 patients would have met the criteria.
We used a single assessment for elevated ALT as a simpliﬁed
method to identify active hepatitis. Under our ‘ALT-based’ assess-
ment, individuals with cirrhosis and those >30 y of age with
ALT>50 IU/L (the upper limit of normal in the local laboratory)
were allocated to treatment. Using the ‘ALT-based’ algorithm
with no assessment of viral replication, the 14 participants with
evidence of cirrhosis were still allocated to treatment, as was 1
of the 6 individuals with active hepatitis. Two of the 81 patients
allocated to observation were allocated to treatment by this
algorithm (Figure 3). Compared with the ‘with HBV DNA’ approach,
this gives a sensitivity of 75% (95% conﬁdence interval [CI] 53.1
to 88.8%) and a speciﬁcity of 97.5% (95% CI 91.3 to 99.6%), a
positive predictive value (PPV) of 88.2% (95% CI 65.7 to 97.9%)
and a negative predictive value (NPV) of 94% (95% CI 86.7 to
97.4%) (Table 2). In a post hoc analysis using any one of cirrhosis
on ultrasound, APRI>2 or ALT>50 (in any age) as an indication for
treatment, a total of 31 patients were identiﬁed (14 with cirrhosis
as above, 17 with elevated ALT). This gives 100% (95% CI 83.9 to
100%) sensitivity but 86.3% (95% CI 77.0 to 92.2%) speciﬁcity,
with an NPV of 100% (95% CI 94.7 to 100%) and a low PPV of
64.5% (95% CI 47.0 to 78.9%).
Figure 1. Standards for Reporting Diagnostic Accuracy Studies (STARD)
diagram showing comparison of ‘ALT-based’ and ‘with HBV DNA’
algorithms.
Table 1. Summary of demographic and clinical details
Female:male, n 54:46
Age (y), median (range) 27 (18–77)
Outpatient:inpatient, n 96:4
ALT (IU/L), median (range) 31 (11–394)
AST (IU/L), median (range) 37 (8–368)
Platelet count (×109/l), median (range) 212 (56–598)
Creatinine (mg/dl), median (range) 1.0 (0.1–2.7)
HBV DNA viral load (IU/ml), median (range) 652 (not detected
–>3.4×108)
Patients with HBV DNA below limit of
quantitation, %
20
Patients with HBV DNA>2000 IU/ml, % 42
Patients with HBV DNA>20 000 IU/ml, % 28
Figure 2. Algorithm for assessment of hepatitis B ‘with HBV DNA’. Based
on WHO guidelines for the prevention, care and management of persons
with chronic hepatitis B 2015.5 Patient ﬂow through the study is indi-
cated in italics. USS: ultrasound scan.
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The test results of the seven participants with discrepant
treatment allocation by the different algorithms are shown in
Table 3. There is a tendency for the ‘ALT-based’ treatment strat-
egy to overtreat transaminitis in those >30 y of age and to
undertreat young patients with active hepatitis compared with
assessment of the same patients using ALT and HBV DNA.
ALT and HBV DNA viral loads are shown for the entire cohort
in Figure 4. The majority of participants had an ALT <50 IU/L and
HBV DNA <20 000 IU/ml (59/100). A group of patients <30 y of
age (circles) had high viral loads and ALTs from 30 to 50 IU/L,
representing ‘immune tolerance’. Three of 29 patients >30 y of
age (triangles) and without evidence of cirrhosis had ALT >50
IU/L, compared with 14/57 patients <30 y of age (p=0.12).
Discussion
Making treatment decisions is a major barrier to rolling out hepa-
titis B therapy programs in the developing world. Established
treatment guidelines such as from the European Association for
the Study of the Liver and the American Association for the Study
of Liver Diseases11–13 require investigations that are costly for
most people. A hepatitis B viral load test in Uganda costs around
US$80, where gross domestic product per capita is US$675. As a
result, both poor access to assessment and unaffordability of
therapy means that millions of people with CHB across the devel-
oping world cannot access life-saving treatment. Simpliﬁed man-
agement strategies based on inexpensive, widely available tests
are an important step towards mobilizing large-scale drug treat-
ment programmes. In response to identiﬁed research gaps5 we
have investigated simpliﬁed assessment of HBV-infected indivi-
duals, based on recommendations from the WHO, that may pro-
vide an accessible alternative to established treatment guidelines.
In our test site, St Mary’s Hospital Lacor, the cost to patients for
all of the tests in the ‘ALT-based’ algorithm is just US$8. The cost
of adding HBV DNA quantiﬁcation to these tests was more than
$1140 per altered treatment decision.
Our study demonstrates the identiﬁcation of a large propor-
tion of CHB patients requiring treatment using only inexpensive
investigations that are widely available to physicians across
Africa. This ﬁnding increases pressure to improve access to
effective HBV treatment. The strength of our approach is the use
of widely available clinical parameters measured in a real-life
health care setting in Uganda. ALT-based assessment is avail-
able to physicians in low-resource settings who want to appro-
priately assess their patients without access to specialist tests.
The NPV of the ‘ALT-based’ approach was high, allowing a large
number of patients to be conﬁdently reassured. The PPV was
high, but the CIs were broad, reﬂecting both the small number
of outcomes and the potential for overtreatment of non-HBV-
related transaminitis. This may be particularly relevant in
Uganda, where alcohol consumption rates are high. We
excluded patients with pre-existing alcoholic liver disease but
did not exclude patients on the basis of alcohol consumption, as
this is an important cofactor for HBV-associated liver disease.
Alcohol consumption is difﬁcult to control for, especially where
the alcohol content of locally produced drinks may be variable
or unknown. The history may be unreliable and serum ethanol is
unlikely to be helpful or feasible. Individuals with signiﬁcant liver
disease and both CHB and signiﬁcant alcohol intake are advised
Figure 3. ‘ALT-based’ algorithm for assessment of hepatitis B. Based on
the WHO guidelines for the prevention, care and management of per-
sons with chronic hepatitis B 2015.5 Simulated patient ﬂow by this
approach is indicated in italics. USS, ultrasound scan.
Table 2. Summary of assessment comparison
Treatment indicated (n=100) Sensitivity, % (95% CI) Speciﬁcity, % (95% CI) PPV, % (95% CI) NPV, % (95% CI)
With HBV DNA 20 – – – –
ALT only 17 75 (53.1 to 88.8) 97.5 (91.3 to 99.6) 88.2 (65.7 to 97.9) 94 (86.7 to 97.4)
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to reduce their alcohol intake as part of their CHB manage-
ment.5 Co-infection with hepatitis C virus (HCV) may have been
a source of non-HBV transaminitis in our cohort, although HCV
prevalence in Uganda is low.22
Important clinical questions remain. First, the ‘with HBV DNA’
assessment is not a true gold standard against which to com-
pare low-cost alternatives. Clinical assessments including a val-
idated, non-invasive measure of ﬁbrosis such as FibroScan
would allow more sensitive detection of early liver disease and
provide a more stringent test for any proposed low-cost
approach. Second, follow-up data to demonstrate whether a
low-cost approach is able to prevent disease outcomes is crit-
ical. It may be that a low-cost algorithm that fails to identify a
proportion of patients in whom treatment is indicated (accord-
ing to rich country guidelines) will still be effective if it can
detect those at highest risk of progression to decompensated
cirrhosis or HCC and prevent these outcomes. Such studies will
require large cohorts with long periods of follow-up. Third, the
false-positive rate of the ‘ALT-based’ algorithm (2/17) is not neg-
ligible. Small-scale overtreatment may be acceptable given the
negligible resistance rates of HBV to tenofovir and favourable
safety proﬁle both in HBV and in the absence of disease.23,24
HIV–HBV co-infected individuals were excluded from this study
and referred to the local HIV treatment programme. Under
Ugandan national HIV guidelines (and WHO guidelines) they
should be treated for both infections with a tenofovir-based
regimen without requiring further assessment of liver disease.
In HIV-endemic areas it may be possible to use tenofovir as
combined HBV treatment and HIV pre-exposure prophylaxis, but
this has not yet been investigated. Unlike in HIV, where clinical
episodes may be used as treatment triggers, the ﬁrst presenta-
tion of CHB disease is commonly with the lethal complications
of HCC or decompensated cirrhosis. As a result, treatment must
be commenced in asymptomatic individuals. Treating those in
need while minimizing overtreatment will be a challenge for any
assessment approach. As we learn more about the conse-
quences of early HBV infection,25 we may see broader indica-
tions for treatment that simplify assessment, as we have seen
with HIV in recent years.26
Our ﬁndings also emphasize the need for improved tests for
ﬁbrosis and active hepatitis, suitable for low-resource settings.
Assessment of cirrhosis by liver ultrasound was important, with
12 of the 20 patients allocated to treatment based on this test.
To roll out a strategy similar to the one we used in this study,
ultrasound provision would have to be improved across rural
Africa. In keeping with previous cohorts, APRI had a poor sensi-
tivity for cirrhosis, with 6 of 12 individuals with cirrhosis on ultra-
sound also having an APRI >2.27 By relying on just ALT, APRI and
HBV DNA without ultrasound, six individuals with signiﬁcant liver
disease would not have been offered treatment. The gamma-
glutamyl transpeptidase (GGT):platelet ratio (GPR), developed by
Lemoine et al.28 and shown to be superior to the APRI in two
cohorts in sub-Saharan Africa, could be incorporated into similar
approaches, although measurement of GGT as part of the liver
function panel is not universal. We did not have access to GGT
locally so could not assess its utility, but this should be the sub-
ject of future prospective studies. It is also notable that the pro-
portion of patients allocated to treatment in our hospital-based
cohort in Uganda was higher than in a community screened
cohort in Gambia reported by the Prevention of Liver Fibrosis
and Cancer in Africa investigators (20% vs 4.4%).17 The propor-
tion observed in our cohort was more similar to the 32% seen in
outpatient settings in the USA,29 suggesting that community
screening approaches may require assessments with higher spe-
ciﬁcity than required by a hospital setting. Even in our relatively
young cohort, many patients were inactive carriers (44/100),
which may keep programmatic treatment costs relatively low,
even in high prevalence areas. Nevertheless, 24 of 57 participants
<30 y of age had ALT>50 IU/ml (14/57) or HBV DNA>20 000 IU/
ml (15/57). Current guidelines emphasize treatment in patients
>30 y of age, but CHB in younger individuals may already be
inducing premalignant lesions.25 Further investigation into the
consequences of hepatitis B on the young are important, particu-
larly in sub-Saharan Africa, where the median age is 18 y.
Conclusions
Inexpensive and accessible assessment such as our ‘ALT-based’
approach should inform trials reporting long-term outcomes as









18 94 1.06 109 132 019 Treat Observe
18 99 1.29 >170 000 000 Treat Observe
22 67 0.62 >170 000 000 Treat Observe
26 128 1.77 2 973 114 Treat Observe
28 135 1.39 198 297 Treat Observe
32 61 0.37 2910 Observe Treat
36 51 0.16 310 Observe Treat
Figure 4. Plot of HBV DNA against ALT. Plot showing log HBV DNA against
ALT for individuals with evidence of cirrhosis (APRI>2 or features of cir-
rhosis on ultrasound, crosses) and those without for ages >30 y and
<30 y (triangles and circles, respectively). Horizontal dotted line indi-
cates ALT>50 IU/ml and vertical dotted line indicates HBV DNA>20 000
IU/ml.
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a basis for scale-up of CHB treatment programmes across the
developing world. There remains a need to optimize manage-
ment for CHB in sub-Saharan Africa based on outcome mea-
sures, including for young individuals. These issues need to be
addressed if the WHO target of a 65% reduction in viral hepa-
titis deaths by 2030 is to be met. While comprehensive outcome
data and improved diagnostic tools are awaited, our pragmatic
approach demonstrates that ‘ALT-based’ assessment is a sim-
ple, achievable way to identify the majority of patients with CHB
who require treatment.
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